Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 265

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Comparison of Nebulized Budesonide and Oral Prednisolone with Placebo in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

MALTAIS, FRANÇOIS, OSTINELLI, JULIETTE, BOURBEAU, JEAN, TONNEL, ANDRÉ BERNARD, JACQUEMET, NADINE, HADDON, JENNIFER, ROULEAU, MICHEL, BOUKHANA, MOHAMED, MARTINOT, JEAN BENOÎT, DUROUX, PIERRE · 2002 · American Journal of Respiratory and Critical Care Medicine

Abstract

Nebulized budesonide has been used successfully to treat acute asthma exacerbation, and we hypothesized that it could also be effective for exacerbations of chronic obstructive pulmonary disease (COPD). In this multicenter, double-blind, randomized, placebo-controlled trial, the efficacy of nebulized budesonide (Pulmicort Respules/Nebuamp), oral prednisolone, and placebo was compared in 199 patients with acute exacerbations of COPD requiring hospitalization. Patients received from randomization (H(0)) to 72 h (H(72)), 2 mg of budesonide every 6 h (n = 71), 30 mg of oral prednisolone every 12 h (n = 62), or placebo (n = 66). All received standard treatment, including nebulized beta(2)-agonists, ipratropium bromide, oral antibiotics, and supplemental oxygen. The mean change (95% confidence interval) in postbronchodilator FEV(1) from H(0) to H(72) was greater with active treatments than with placebo: budesonide versus placebo, 0.10 L (0.02 to 0.18 L); prednisolone versus placebo, 0.16 L (0.08 to 0.24 L). The difference in FEV(1) between budesonide and prednisolone was not significant, -0.06 L (-0.14 to 0.02 L). The occurrence of serious adverse events was similar for all groups. Budesonide had less systemic activity than prednisolone as indicated by a higher incidence of hyperglycemia observed with prednisolone. Both budesonide and prednisolone improved airflow in COPD patients with acute exacerbations when compared with placebo. Nebulized budesonide may be an alternative to oral prednisolone in the treatment of nonacidotic exacerbations of COPD but further studies should be done to evaluate its long-term impact on clinical outcomes after an initial episode of COPD exacerbation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/ajrccm.165.5.2109093

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 265

Metadata

Authors
MALTAIS, F., OSTINELLI, J., BOURBEAU, J., TONNEL, A. B., JACQUEMET, N., HADDON, J., ROULEAU, M., BOUKHANA, M., MARTINOT, J. B., & DUROUX, P.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2002-03-01
Volume
165
Issue
5
Pages
698-703
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W1929470552
Cited by
265
References
12
FWCI
12.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Nebulized Budesonide and Oral Prednisolone with Placebo in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1164/ajrccm.165.5.2109093
The paper
MALTAIS, F., OSTINELLI, J., BOURBEAU, J., TONNEL, A. B., JACQUEMET, N., HADDON, J., ROULEAU, M., BOUKHANA, M., MARTINOT, J. B., & DUROUX, P. (2002). Comparison of Nebulized Budesonide and Oral Prednisolone with Placebo in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/ajrccm.165.5.2109093

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.